Edgewise Therapeutics announces public offering of 11.6M shares at $10.32/share, expected gross proceeds $120M

Edgewise Therapeutics, Inc.

Underwritten 11,627,907 shares; underwriters have 30-day option for additional 1,744,186 shares.
Public offering price $10.32/share; underwriters purchase at $9.70/share.
Expected gross proceeds of $120M before offering expenses; closing expected September 16, 2022.
Offering made via effective S-3 registration statement (333-264083); J.P. Morgan and SVB Securities as representatives.
Underwriting agreement includes customary representations, warranties, and indemnification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.